aCLINICAL INVESTIGATION AGREEMENT FOR THE DRUGS BETWEENClinical Investigation Agreement • January 24th, 2022
IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA, headquartered in Via Albertoni 15, 40138 Bologna, tax code: 92038610371, VAT registration number: 02553300373, legally represented by the Director of the U.O.C. Research and Innovation, Dott.ssa Luigia Scudeller, delegated to sign this deed under the resolution no. 28 of 02/02/2018, as confirmed by resolution no. 255 of 31/10/201 (hereinafter the “Entity")
CLINICAL INVESTIGATION AGREEMENT FOR MEDICAL TECHNOLOGY INDUSTRY SPONSORED RESEARCH IN SCOTTISH HEALTH BOARDS [Name – Clinical Investigation] This agreement dated …………………………………… is between […. insert name….] Health Board, constituted pursuant to the...Clinical Investigation Agreement • February 1st, 2021
WHEREAS the Sponsor is a medical technology company involved in the research, development, manufacture and sale of medical devices for use in humans
Instruction Pages The information set out below provides a checklist of information that needs to be included in the model Clinical Investigation Agreement (mCIA) in preparation for execution by the Parties. It is the Sponsor’s responsibility to...Clinical Investigation Agreement • December 13th, 2023
Add, remove and / or update recitals as applicable to the Clinical Investigation (as a preamble to the Agreement, such changes do not constitute modification to the template Agreement). Recital D should be completed where a corporate Affiliate of the Sponsor is formally empowered by the Sponsor to sign the Agreement on behalf of the Sponsor thereby binding the Sponsor as Party to the Agreement (and should be removed where this is not the case). Recital E should be retained if the Trial Site is in Northern Ireland and otherwise deleted.
AGREEMENT FOR CLINICAL INVESTIGATIONClinical Investigation Agreement • October 13th, 2021
(insert name of Healthcare Facility) (hereinafter the “Entity"), headquartered in tax code and VAT no. , through its Legal Representative, , in the capacity of (indicate whether Director General CEO, Extraordinary Commissioner, etc.), who has granted (position of signatory) (hereinafter “ ”) with the powers to enter into this Agreement
Confidential (HEARTWARE LOGO) CLINICAL INVESTIGATION AGREEMENT THIS CLINICAL INVESTIGATION AGREEMENT (this "Agreement") made and effective as of this 17th day of February, 2006 (the "Effective Date"), is by and between Heartware, Inc., a Delaware...Clinical Investigation Agreement • April 30th, 2007 • HeartWare LTD • Florida
CONTRACT FOR CONDUCTING CLINICAL INVESTIGATIONClinical Investigation Agreement • March 23rd, 2023
(please indicate the name of the health structure) henceforth called “Institution”, with registered office in Tax Code and VAT No. , in the person of the Legal Representative, , as (please indicate if General Manager, Chief Executive Officer, Extraordinary Commissioner, etc.), who has appropriate powers to sign this Act on (qualification of the signatory),
Please note: This document contains text in red/italic and brackets, where text is either optional, or text is to be inserted to adjust to the clinical investigation in question.] Standard Clinical Investigation Agreement Agreement on the conduct of a...Clinical Investigation Agreement • October 14th, 2020
Dr. xx (“Investigator”) will be responsible for the conduct of the Investigation on behalf of Institution/Site. It is understood that Investigator is not a party to this Agreement but is bound by his/her employment to the Institution/Site to abide by the terms herein.
CLINICAL INVESTIGATION AGREEMENTClinical Investigation Agreement • July 7th, 2021
This clinical investigation agreement (“Agreement”) is entered into as of the last date of the signature below (“Effective Date”) between
DRAFT AGREEMENT FOR CLINICAL INVESTIGATION Study Investigational Plan n° [INSERT NUMBER] Center: [INSERT NUMBER]Clinical Investigation Agreement • May 30th, 2016
BETWEEN Universitaire Ziekenhuizen Leuven Herestraat 49, 3000 Leuven, Belgium duly represented by its Chief Executive Officer, Prof. Dr. [INSERT NAME], hereinafter referred to as the “INSTITUTION”,
Instruction Pages The information set out below provides a checklist of information that needs to be included in the Contract Research Organisation model Clinical Investigation Agreement (CRO-mCIA) in preparation for execution by the Parties. It is...Clinical Investigation Agreement • December 13th, 2023
Add, remove and / or update recitals as applicable to the Clinical Investigation (as a preamble to the Agreement, such changes do not constitute modification to the template Agreement). Recital E should be completed where a corporate Affiliate of the Sponsor is formally empowered by the Sponsor to sign the Agreement on behalf of the Sponsor thereby binding the Sponsor as Party to the Agreement (and should be removed where this is not the case). Recital F should be retained if the Trial Site is in Northern Ireland and otherwise deleted.
CLINICAL INVESTIGATION AGREEMENT FOR MEDICAL TECHNOLOGY INDUSTRY SPONSORED RESEARCH IN NHS HOSPITALS [Name – Clinical Investigation] This agreement dated …………………………………… is between […. insert name of NHS Organisation], of [.…insert address….]...Clinical Investigation Agreement • November 19th, 2020 • England and Wales
WHEREAS the Sponsor is a medical technology company involved in the research, development, manufacture and sale of medical devices for use in humans
CLINICAL INVESTIGATION AGREEMENT between [Sponsor] and [Hospital] HF and INVEN2 AS Clinical Investigation Title […] Protocol no: […] Investigation Site [Hospital, Department] Principal Investigator Inven2 reference no: […] […]Clinical Investigation Agreement • November 11th, 2020
[The parties can be redefined, for example if a CRO is a contracting party agreeing under its own name or for the Sponsor. In any case the Sponsor is bound to the sponsor’s responsibilities in accordance with ICH GCP and the applicable law. The division of tasks between CRO and Sponsor should be clear and match the separate agreement between Sponsor and CRO.
CLINICAL INVESTIGATION AGREEMENT FOR THE DRUGSClinical Investigation Agreement • July 31st, 2020
_ _ _ (indicate whether Director General, CEO, Extraordinary Commissioner, etc.), who has granted _ , (position of signatory) (hereinafter ” ”) with the powers to
AGREEMENT FOR CONDUCTING A CLINICAL INVESTIGATION ON THE MEDICAL DEVICE WITHOUT CE MARKING OR NOT MARKED FOR THE USE FOR WHICH IT IS INTENDED SONOCLEAR ACF CLINICAL INVESTIGATION CONTRATTO PER LA CONDUZIONE DI INDAGINE CLINICA SUL DISPOSITIVO MEDICO...Clinical Investigation Agreement • March 23rd, 2023
BETWEEN Fondazione IRCCS Istituto Neurologico Carlo Besta (“Institution”), with registered offices in Milan, Italy, Via Celoria no. 11, Tax code 01668320151 and VAT number 04376340156, represented by the General Manager, Dr Angelo Cordone, by delegation of the signing power conferred by Resolution of the Board of Directors no. V / 37 of 1/7/2019, domiciled for the office at the aforementioned Institution; AND (a) SonoClear AS, headquartered in Trondheim, Norway, VAT no. 917956146,through its Legal Representative Peter Balmforth, in the capacity of Chief Executive Officer (CEO) (hereinafter the “Sponsor”) (b) (If mandate given to the CRO) Qmed Consulting A/S, headquartered in Koebmagergade 53, 1. DK-1150 Copenhagen K., Denmark VAT no. DK30564278, through its Legal Representative, Helene Quie Hansen in the capacity of Chief Commercial Officer, (hereinafter the "CRO"), acting in the name and on behalf of/in its own name and on behalf of/in the interests of SonoClear AS (hereinaf
Fakultní nemocnice Olomouc, xxxxxxxxxxxxxxxClinical Investigation Agreement • February 24th, 2022
CLINICAL INVESTIGATION AGREEMENT This CLINICAL INVESTIGATIONAGREEMENT (the “Agreement”) is effective on the day of the publishing in accordance with the Act no. 340/2015 Coll. On the Register of Contracts (the “Effective Date”), by and between Fakultní nemocnice Olomouc located at I.P. Pavlova 185/6, 779 00 Olomouc, Czech Republic, represented by Prof. MUDr. Roman Havlík, PhD., director, IČO (Company ID): 00098892 (the “Institution” or “Site”), Pharmaceutical Research Associates CZ, s.r.o., located at Prague 7 Jankovcova 1569/2c Postal Code 170 00 Czech Republic (“PRA”), an affiliate of PHARMACEUTICAL RESEARCHASSOCIATES, INC., located at 4130 Park Lake Avenue, Suite 400 Raleigh North Carolina 27612 US (“PRA INC.”), acting as an independent contractor for NANOBIOTIX S.A., located at 60 rue de Wattignies, 75012 PARIS, France, VAT ID: FR34447521600 (the “Sponsor”). PRA has agreed to accept certain obligations and duties of PRA INC. in respect of the conduct of the clinical trial in Czech
CLINICAL INVESTIGATION AGREEMENTClinical Investigation Agreement • February 22nd, 2022
AGREEMENT (the “Agreement”) is effective from the day of its publication in the Register of Contracts in accordance with the Act on the Register of Contracts (the “Effective Date”), by and between
SUL DISPOSITIVO MEDICO NON MARCATO CE OPPURE NON MARCATO PER L’UTILIZZO CUI È DESTINATO [Nome dispositivo medico] INDAGINE CLINICA AGREEMENT FOR CLINICAL INVESTIGATION ON THE MEDICAL DEVICE WITHOUT CE MARKING OR NOT MARKED FOR THE USE FOR WHICH IT IS...Clinical Investigation Agreement • May 23rd, 2021
la Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico (di qui poi indicata come “Ente”) con sede in Milano e domicilio fiscale in Via Francesco Sforza n. 28 – CAP 20122 Milano, Codice Fiscale e Partita IVA 04724150968, nella persona del Direttore Generale Dott. Ezio Belleri the Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico (hereinafter the “Entity”), headquartered in Milan and tax domicile at Via Francesco Sforza n. 28 – CAP 20122 Milano, Tax Code and VAT Number 04724150968, in the person of its Director General Dr. Ezio Belleri
ZMLUVA O KLINICKOM SKÚŠANÍ CLINICAL INVESTIGATION AGREEMENTClinical Investigation Agreement • March 12th, 2020
concluded pursuant to Section 269 (2) of Act no. 513/1991 of Coll., the Commercial Code, as amended (hereinafter referred to as the “Commercial Code”) (hereinafter referred to as the “Agreement”)
ContractClinical Investigation Agreement • December 13th, 2016
Clinical Investigation Agreement Smlouva o provedení klinické zkoušky Repetitive Activation Patterns and Focal Impulses Identification and Ablation in Persistent AF using the RHYTHMFINDER-192 RAPID-AF(RF-171) Repetitive Activation Patterns and Focal Impulses Identification and Ablation in Persistent Af using the RHYTHMFINDER-192 RAPID-AF(RF-171) This is an agreement (“Agreement”) made by and between:Nemocnice České Budějovice, a.s.,having its registered office located at B.Němcové 585/54, Postal Code: 370 01,Company ID No. 260 68 877, registered in the Business Register administered by the District Court of České Budějovice, Section B, Rider 1349, represented by MUDr. Břetislav Shon, Chairman of the Board of Directors, and MUDr. Jaroslav Novák, MBA, Vice-Chairman of the Board of Directors, Tuto smlouvu (dále jen „smlouva“) uzavírají smluvní strany:Nemocnice České Budějovice, a.s.se sídlem v Českých Budějovicích, B. Němcové 585/54, PSČ 370 01, IČ 260 68 877,zapsan é v obchodním rejs
FIRST AMENDMENT OF CLINICAL CLINICAL INVESTIGATION AGREEMENT FOR THE DRUGSClinical Investigation Agreement • August 17th, 2022
– 20128 Torino (Italy) (hereinafter “Entity”) and University of Turin, Department of Biological and Clinical Sciences (hereinafter the “University”) with registered office in Turin, Via Verdi 8 and administrative office in Orbassano, Regione Gonzole 10, Italy, and Gilead Sciences, Inc., having its principal address at 333 Lakeside Drive, Foster City, California 94404 (together with its affiliates and subsidiaries “Gilead” (hereinafter the “Sponsor”). Capitalized terms used herein but not defined herein will have the meanings ascribed to such terms in the Agreement. Entity, University and Gilead are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
ContractClinical Investigation Agreement • June 10th, 2021
CLINICAL INVESTIGATION AGREEMENT FOR THE DRUGS “A Randomized, Dose-finding and Confirmatory, Double-blind, Placebo-controlled, Parallel-group Multicenter Study with a 2-Stage Adaptive Design and Randomized Withdrawal to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age with Childhood Absence Epilepsy or Juvenile Absence Epilepsy " BETWEEN Fondazione IRCCS Istituto Neurologico Carlo Besta (hereinafter referred to as “Institution”), with registered office at Milano, via Celoria 11Tax Code no. 01668320151 and VAT no. 04376340156, in the person of the General Manager, dott. Paola Lattuada, who signs this deed by virtue of the delegation of the power of signature conferred by the Board of Directors' Resolution. n. V / 37 of 1/7/2019, domiciled for the office at the aforementioned Institute represented by its Legal Representative AND UCB BIOSCIENCES GMBH, headquartered in Alfred-Nobel-Strasse 10, 40789 Monheim, Germany , V
IS BETWEEN ROYAL BROMPTON & HAREFIELD NHS TRUST OF SYDNEY STREET, LONDON SW3 6NP UK (HEREINAFTER KNOWN AS THE "TRUST") AND HEARTWARE, INC. 3351 EXECUTIVE WAY MIRAMAR, FL 33023-3935 U.S.A. (HEREINAFTER KNOWN AS THE "SPONSOR") NOWClinical Investigation Agreement • April 30th, 2007 • HeartWare LTD
ContractClinical Investigation Agreement • March 6th, 2023
Stamp duty paid using the virtual system pursuant to Art. 15 of Presi- dential Decree 642 of 1972 - Application Reference no. 0283360 of 24 November 2017 – Authorization Reference no. 294901 of 07 December 2017 Agenzia delle Entrate Provinciale II di Milano, Ufficio Territoriale di Gorgonzola [Second Provincial Italian Revenue Agency of Milan, Gorgonzola Branch] CLINICAL INVESTIGATION AGREEMENT FOR THE DRUGS“A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants with Active Sub- acute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus with or without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)” Imposta di bollo assolta in maniera virtuale ex art. 15 del D.P.R. 642 del 1972 - Protocollo Istanza n. 0283360 del 24 Novembre 2017 – Proto- collo Autorizzazione n. 294901 del 07 Dicembre 2017 Agenzia
